News | August 02, 2024
Aster DM Healthcare posts Q1 FY25 PAT at Rs. 74 Cr
Q1 FY25 revenues up 20% YoY to Rs. 1,002 crore
Q1 FY25 revenues up 20% YoY to Rs. 1,002 crore
GSK and Flagship to jointly fund up to $150 million upfront
Acquisition in line with Mankind’s stated objective to expand its presence in high entry barrier complex portfolios and high potential OTX brands
Enhanced collaboration under the Memorandum of Cooperation (MoC) between India and Japan in medical product regulations
Olverembatinib, a novel drug developed by Ascentage Pharma with support from the National Major New Drug Development program
Felzartamab demonstrated positive interim results from the Phase 2 IgA nephropathy (IgAN) study
CureVac receives €400 million upfront and up to an additional €1.05 billion in development, regulatory and sales milestone payments as well as tiered royalties; all previous financial considerations from the prior collaboration agreement replaced
The expiry date of almost all strips is rubber stamped vanish in a matter of 3 to 4 months, making the remaining tablets waste for subsequent use before expire date
An investigational CYP11A1 Inhibitor, for the treatment of metastatic castration-resistant prostate cancer
Aster CMI Hospital has successfully implemented several key digital health initiatives contributing to this accreditation
Subscribe To Our Newsletter & Stay Updated
